Page last updated: 2024-10-25

deferoxamine and Chronic Kidney Diseases

deferoxamine has been researched along with Chronic Kidney Diseases in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
David, V1
Martin, A1
Isakova, T1
Spaulding, C1
Qi, L1
Ramirez, V1
Zumbrennen-Bullough, KB1
Sun, CC1
Lin, HY1
Babitt, JL1
Wolf, M1

Other Studies

1 other study available for deferoxamine and Chronic Kidney Diseases

ArticleYear
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
    Kidney international, 2016, Volume: 89, Issue:1

    Topics: Animals; Autoantigens; Cell Line; Collagen Type IV; Deferoxamine; Femur; Fibroblast Growth Factor-23

2016